Transcriptomic profiling of YAP/TAZ and their downstream effectors—such as CTGF and CYR61—allows quantitative assessment of pathway activation and can predict sensitivity to YAP–TEAD inhibitors like verteporfin in breast cancer and glioblastoma models (Zhao et al., 2023; Lv and Zhou, 2020). The gene discussed is YAP1; the disease is glioblastoma.